Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Match Group Inc (MTCH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Match Group Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $279.68 (market cap $39.89B), while Match Group Inc trades at $38.92 (market cap $9.06B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 4.4× Match Group Inc's market cap, and Match Group Inc pays a 2.06% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | MTCH | |
|---|---|---|
Market Cap | $39.89B | $9.06B |
Sector | Health | Media |
52-Week High | $491.22 | $39.32 |
52-Week Low | $278.09 | $28.90 |
Enterprise Value | $38.15B | $12.01B |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
MTCH trades at $38.85, down 1.2% today, with a bullish technical signal from moving averages and key support at $38. The company shows solid fundamentals with a P/E of 14.83, net income margin of 18.83%, and three consecutive quarterly earnings beats. Revenue growth remains stable at $3.49B for 2025, while cash flow from operations improved to $1.08B. Recent news highlights a turnaround focus, including Tinder's AI features and Hinge's growth.
The outlook is positive with a consensus price target of $41.63, implying 7% upside. Analyst sentiment is bullish (53% Buy), but risks include high long-term debt of $3.85B and competitive pressures in dating apps. Earnings growth and debt management are critical for sustained stock appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →
